Salim Dhanji
Chief Executive Officer bij ME THERAPEUTICS HOLDINGS INC.
Vermogen: 14 M $ op 31-03-2024
Profiel
Salim Zulifkar Dhanji is currently the Chief Executive Officer & Executive Director at ME Therapeutics Holdings, Inc. since 2023 and the President at Perceptive Property Development since 2013.
He previously worked as the Director-Preclinical Research at Qu Biologics, Inc. from 2009 to 2014.
Dr. Dhanji received his undergraduate degree in 2001 and his doctorate in 2006 from the University of British Columbia.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 05-02-2024 | 4 175 143 ( 17.72% ) | 14 M $ | 31-03-2024 |
Actieve functies van Salim Dhanji
| Bedrijven | Functie | Begin |
|---|---|---|
| ME THERAPEUTICS HOLDINGS INC. | Chief Executive Officer | 09-03-2023 |
Eerdere bekende functies van Salim Dhanji
| Bedrijven | Functie | Einde |
|---|---|---|
Qu Biologics, Inc.
 Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Corporate Officer/Principal | 01-01-2014 |
Opleiding van Salim Dhanji
| University of British Columbia | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Qu Biologics, Inc.
Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Health Technology |
| ME Therapeutics Holdings, Inc. |
